Johnson and Johnson looking like an underrated blue chip stock. I'm thinking buy. It's got all the hallmarks of an undervalued, solid foundation. The yield is just under 3% which is higher than the S&P500, but the company carries a fraction of the risk. If you put $10,000 today, the compounding interest would accumulate into deep six figures over two decades. And for what risk? That people stop getting sick?
Johnson & Johnson
JNJ
NYSE
IPO1944
about JNJ
Johnson & Johnson is a global healthcare company that focuses on the development and sale of pharmaceuticals and medical technology. Its pharmaceutical division, known as Innovative Medicine, creates prescription drugs for a wide range of diseases, while its MedTech division manufactures and sells a broad portfolio of surgical equipment, orthopedic products, and other medical devices.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $178.00 | $179.50 | $176.56 | $429.72B | 9.73M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$2.30 | 18.11 | 18.22 | 27.34% | 23.32% | 2.91% |
